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Purpose of Review 
This review summarizes the most recent evidence regarding the effects of diet in preventing 
and reducing age-related cognitive decline and neurodegenerative diseases.  
 
Recent Findings 
Recent evidence indicates that nutraceuticals and whole diet approaches may protect 
against the development of age-related cognitive decline and pathological 
neurodegeneration. The neuroprotective effects are diverse depending on the nutrient 
employed and may involve a reduction of neuroinflammation, an activation of the 




This review summarizes the existing evidence in favour of diet as a viable alternative 
approach to directly impact cognitive decline and neurodegenerative disease. The single 
nutrient (polyphenols, B vitamins, long-chain polyunsaturated fatty acids) versus whole diet 
approach (Mediterranean diet, DASH, MIND, Nordic, ketogenic) is presented and 
discussed. Potential mechanisms of action underlying the beneficial effects of these diets 
are also described. Implementation of large-scale preventive interventions based on dietary 
patterns identified as being beneficial to brain health should be a research and public health 
priority, ideally in conjunction with other health-promoting lifestyle factors. 
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INTRODUCTION 
It has been estimated that 50 million people worldwide suffer from Alzheimer’s disease (AD), 
the most common type of dementia. If no breakthrough can be made to prevent the disease 
or delay its onset, the number of patients is anticipated to reach 152 million by 2050 (1). 
Assuming a curvilinear association between age and dementia risk, a 2 year delay in onset 
would reduce population incidence by 22% by 2047 (2), resulting in 25 million fewer cases 
worldwide (3). Existing drug treatments for neurodegenerative conditions rarely curtail the 
underlying disease processes, and consequently there is an urgent need to develop 
alternative strategies to directly prevent, slow, and even stop neurodegeneration. Lifestyle 
strategies such as nutritional interventions have potential to be a safe, cheap, and effective 
alternative to protect against age-related cognitive decline and neurodegeneration, resulting 
in significant personal and societal benefits (4). This review aims to summarise the existing 
evidence in favour of diet either in form of nutraceuticals or whole diet as a viable alternative 
approach to directly impact cognitive decline and neurodegenerative disease. Some 
mechanistic considerations will also be described. 
 
NUTRACEUTICALS 
Accumulating evidence indicates that nutraceuticals such as polyphenols, B vitamins, 
polyunsaturated fatty acids (PUFAs) and other nutritional components can have beneficial 
effects on cognitive impairment associated to normal aging and/or neurodegenerative 




Polyphenols are a large family of phytochemicals widely distributed in the plant kingdom and 
present in fruits, vegetables, nuts, seeds, flowers and other plants used for human 
consumption. They can be classified according to the number of phenol rings presented and 
the structural components that bind these rings in phenolic acids (hydroxycinnamic and 
hydroxybenzoic acids), flavonoids (benzene rings) and less common stilbene and lignans, 
although other categorizations exist (5). Previous research has demonstrated that different 
purified polyphenols such as resveratrol, curcumin, anthocyanin, ferulic acid, catechin and 
epicatechin were able to prevent cognitive decline in experimental animal models of aging 
and degenerative diseases (6-10). A plethora of observational and intervention studies 
observed a positive correlation between cognitive decline and the supplementation of 
different products rich in polyphenols like cocoa, berries, green tea and grape (11-15). 
However, not all studies investigating the effects of polyphenols on cognitive decline 
reported positive results. A recent meta-analysis of 34 clinical trials concluded that although 
some polyphenols might improve specific markers of cognitive status, definitive 
recommendations for the use of these compounds in the prevention of cognitive decline are 
currently not applicable (16). This is partly due to differences between individuals in the 
absorption, distribution, metabolism and excretion of bioactive compounds (17) as well as 
to heterogeneity in their biological response (18). The major determinants responsible for 
the between‐subject variability may include genetic (Single Nucleotide Polymorphisms) and 
non‐genetic factors (gut microbiota composition, sex, age, dietary habits, etc) which are only 
beginning to be explored and may differ depending on the compounds (19). 
 
B-Vitamins 
B vitamins have been suggested to have a positive effect on cognitive functions thanks to 
their ability to counteract the increase of homocysteine during aging that is related to 
cognitive impairment (20, 21). A randomized, double blind, placebo controlled study that 
involved 818 participants aged 50–70 years, evidenced that a supplementation of 800 
g/day of folic acid significantly improved domains of cognitive function that tend to decline 
with age (22).  The clinical trial (VITACOG) demonstrated that B‐vitamin supplementation 
(folic acid 0.8 mg, vitamin B6 20 mg, vitamin B12 0.5 mg) for 2 years in participants aged 70 
years and over with MCI reduced average brain atrophy rate (23, 24), ameliorated global 
cognition, episodic memory  and semantic memory (25). Furthermore, the Singapore 
Chinese Health Study including 16,948 participants showed that higher dietary intakes of 
riboflavin and folate in midlife were associated with a lower risk of cognitive impairment in 
later life in the Chinese population (26). However, a recent meta-analysis evidenced 
conflicting results on cognitive outcomes of B-vitamin supplementations due to the great 
variability of the existing trials in terms of type of supplementations, population sampled, 
study quality, and duration of treatment (27).  
 
Long chain polyunsaturated fatty acids (LC-PUFAs)  
Neuronal cell membranes are particularly enriched in LC-PUFAs, important for the optimal 
development and function of the brain and the nervous system (28). The two most important 
types of LC-PUFAs in the human brain are eicosapentaenoic acid (EPA: 20:5 ω-3) and 
docosahexaenoic acid (DHA: 22:6 ω-3) (29). Although different studies evidenced an 
association between endogenous low levels of omega-3 and cognitive impairment and 
Alzheimer’s disease (30, 31), the effects of ω-3 LC-PUFAs supplementation on cognitive 
outcomes in randomized clinical trials remain controversial. In a randomized, double-blind, 
placebo-controlled study, healthy older adults (62-80 years) with subjective memory 
impairment receiving 2.4 g/d PUFAs for 24 weeks induced an increase in working memory 
performance (32).  The administration of DHA-enriched meals to subjects (n = 75; 88.5 ± 
0.6 years) with cognitive impairment, living in nursing homes, protected against age-related 
cognitive decline (33).  On the other hand, in a recent very large trial involving 1680 
participants, a daily dose of 800 mg DHA and 225 mg EPA had no significant effects on 
cognitive decline over 3 years in elderly people aged 70 years or older with memory 
impairment (34). A meta-analysis of prospective cohort studies found no statistical evidence 
for an inverse association between ω-3 LC-PUFAs intake and risk of dementia or AD (35). 
Yassine et al. (36) suggested that the different outcomes of the ω-3 supplementations 
studies on cognitive decline may be, in part, explained by the interactions among DHA, 
APOE genotype, and stage of AD pathologic changes. They demonstrated that DHA 
supplementation in predementia but not in AD dementia may reduce the risk for or delay the 
onset of AD symptoms in APOE4 carriers. 
 
DIETARY PATTERNS 
An increasing number of studies are highlighting the synergic effect of different natural 
compounds when administered in combination (37-39). Taking into account the complex 
biological mixture of different components of the diet, it has been suggested that the use of 
a diet approach rather than the supplementation of single components might help to 
prevent/counteract cognitive decline in elderly people.  
 
Mediterranean diet 
The Mediterranean diet (MeDi), the traditional dietary pattern followed by people residing on 
the shores of the Mediterranean Sea, is characterized by a high intake of vegetables, 
legumes, fruits, cereals, fish, and extra virgin olive oil, moderate consumption of alcohol and 
low-to moderate intake of meat and dairy products. It is undoubtedly the most extensively 
studied dietary pattern, and more and more evidence suggest a potential protective role 
against cognitive decline and dementia. 
Two clinical trials (40, 41), part of the larger trial PREDIMED (42), investigated the effect of 
MeDi in combination with nuts or extra virgin olive oil (EVOO) and found improved cognitive 
function with the MeDi supplemented with either EVOO oil or nuts vs. low-fat diet. These 
trials, despite having a realistically long follow-up (4·1–6·5 years), have the limitation to 
consider relatively few participants. The key role of EVOO in relation to the positive effects 
of the MeDi was reinforced by the findings of Mazza et al. (43) who observed improved 
cognitive functions in elderly following the MeDi in which all the oils were substituted with 
EVOO for 1 year in respect to subjects following the MeDi alone.  
Different meta-analyses evidenced a positive effect of MeDi on cognitive function. In 
particular, Sofi et al. (44) reported a 13% reduced risk of neurodegenerative diseases in 
individuals who most adhered to the MeDi. Similarly, Psaltopoulou et al. (45) evidenced that 
moderate and high adherence to MeDi is consistently associated with reduced risk for 
cognitive impairment. However, not all the studies totally agreed on the Medi positive effects 
on cognition. A systematic review reported that most of the randomized controlled trials 
published until 2018 found no significant association between MeDi and reduction of 
cognitive decline, and very few showed a small effect sizes (46). However, significant and 
clinically meaningful effect sizes were found for cognitive composites in the largest and most 
robust trial, indicating promising scope for future well-designed trials. 
 
DASH diet 
The Dietary Approaches to Stop Hypertension (DASH) diet was initially designed to prevent 
hypertension and is relatively low in saturated fat, total fat, and cholesterol; moderately high 
in protein; and high in minerals and fibres (47). Of the three studies which investigated the 
effect of DASH diet on cognitive function in the elderly, two studies reported a positive 
outcome (48, 49), meanwhile one did not evidence any effects (50). In particular, a study 
including 923 elderly men and women reported modest but positive links between the 
highest tertile of DASH diet adherence and lower rates of AD (49). The Nurse’s Health Study 
observed that a higher adherence to DASH diet was associated with improved global 
cognition and verbal memory (48). On the contrary, the Women’s Health Initiative Memory 
Study (WHIMS) (50) reported that DASH diet adherence was not associated with a lower 
incidence of MCI or dementia in old women. The impact of DASH diet on cognition is just 




The MIND diet is a combination of the MeDi and DASH diets but with slight modifications 
taking into account the best evidence for neuroprotection. Three cohort studies evidenced 
a positive effect of MIND diet on cognitive function. For example, Morris et al. showed that 
MIND diet score was associated with a slower rate of cognitive decline equivalent to 7.5 
years of younger age among the participants in the top third of MIND diet scores compared 
with the lowest third (51). In a subsequent study, they found that high and moderate 
adherence to MIND diet was associated with a decrease in AD risk (49). The US Nurse’s 
Health Study investigated the effect of the MIND diet on 16,058 older women aged 70 and 
over for 6 years and found that long-term adherence to the MIND diet was moderately 
associated with better verbal memory in later life, but not association was evidenced with 
global cognition, verbal memory or telephone interview of cognitive status (52). Future 




The Nordic diet attempts to reflect the diet consumed in Nordic countries and is 
characterized by high intakes of fish, apples and pears, cabbages, root vegetables, whole 
grains from oat, barley and rye, berries, low-fat dairy products, potatoes and rapeseed oil 
(53). A large population-based cohort study that followed a total of 2223 dementia-free 
adults aged ≥60 for 6 years observed that moderate to high adherence to Nordic diet was 
more closely associated with less cognitive decline than moderate to high adherence to the 
other healthful dietary pattern such as MeDi, DASH and MIND (54). Another study carried 
out in subjects aged 57–78 years revealed that better adherence to the Nordic diet had been 
associated with higher scores in global cognition over a 4-year study period after adjustment 
for demographic and lifestyle factors in individuals with normal cognition (55). Consumption 
of a Nordic diet appears to display a positive association with cognition in individuals with 
normal levels of cognition, however, whether such might improve cognition in population 
with cognitive decline remains to be established.  
 
Ketogenic diet 
In the last years, different studies suggested the ketogenic diet (KD), characterized by high 
fat, moderate protein and very low carbohydrate composition, as a tool to prevent the 
consequences of age-related cognitive decline. In aged rats the KD improved cognitive 
performance under normoxic and hypoxic conditions, meanwhile motor performance where 
not affected (56). Two studies carried out in mice found that KD initiated in young adulthood 
extend midlife longevity and improve cognition (57, 58). A recent study, observed that a late-
life KD intervention improved behaviour on both the elevated figure-8 maze alternation task 
and on cognitive dual task that required working memory while simultaneously performing a 
bi-conditional association task in rats (59). Such data were recently confirmed in a 
preliminary human study, demonstrating that the generation of even trace ketones might 
enhance episodic memory and patient-reported vitality in very early AD (60). Future studies 
are however necessary to confirm these preliminary results. 
 
MECHANISMS UNDERLYING THE IMPACT OF DIET 
Several studies support a relationship between neuroinflammation and nutrients, foods or 
dietary patterns, taking into account the synergistic or antagonistic biochemical interactions 
among nutrients as well as the different food sources of the same nutrient. Natural 
antioxidant compounds found in plant foods and particularly those found in berries (such as 
strawberry, blueberry, blackcurrant, blackberry, blueberry and mulberry) have been 
proposed to exert a multiplicity of neuroprotective actions within the brain, including a 
potential to protect neurons against injury induced by neurotoxins, an ability to suppress 
neuroinflammation and a potential to promote memory, learning, and cognitive functions 
(61-63). Whether the dietary bioactive compounds can cross the Blood Brain Barrier (BBB) 
in order to play a direct anti-inflammatory or pro-inflammatory effect on microglia and/or 
other Central Nervous System (CNS) cells is still unclear. Another hypothesis is that they 
may trigger a peripheral reaction that indirectly induces a CNS response. The subsequent 
synthesis of cytokines may drive microglia polarization and promote immune-to-brain 
signalling (64).  
The ketogenic diet, originally developed for the treatment of epilepsy in non-responder 
children, is spreading to be used in the treatment of many diseases, including older adults 
at risk for AD (65). The main activity of the ketogenic diet has been related to improved 
mitochondrial function and decreased oxidative stress. beta-Hydroxybutyrate, the most 
studied ketone body, has been shown to reduce the production of reactive oxygen species 
(ROS), and to improve mitochondrial metabolism. In particular, it stimulates the cellular 
endogenous antioxidant system with the activation of nuclear factor erythroid-derived 2-
related factor 2 (Nrf2), modulates the ratio between the oxidized and reduced forms of 
nicotinamide adenine dinucleotide (NAD⁺/NADH) and increases the efficiency of electron 
transport chain through the expression of uncoupling proteins. Furthermore, the ketogenic 
diet performs anti-inflammatory activity by inhibiting nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-kB) and the nucleotide-binding domain, leucine-rich-
containing family, pyrin domain-containing-3 (NLRP3) inflammasome as well as by inhibiting 
histone deacetylases (HDACs), therefore improving memory encoding (66, 67).  
In order to combat oxidative stress and produced ROS, ascorbic acid and vitamin E have 
been extensively used. Whilst their combined use has provided positive results, the single 
use of ascorbic acid, despite encouraging results obtained in vitro and in vivo, has not 
proven to be particularly useful in the treatment of AD, although its deficiency plays an 
important role in accelerating amyloid accumulation (68). Ascorbic acid also affects 
inflammageing by decreasing the amount of IL-6 and IL-8, two cytokines involved in the 
production of ROS (69, 70).  
Research over the past two decades has indicated that the gut microbiome and it’s 
interaction with dietary compounds have important implications for human health (71). 
Polyphenols, for example, favour the growth of beneficial symbiotic bacteria and counteract 
the growth of pathogens (61). Similarly, omega-3 fatty acids  and KD were also reported to 
affect microbiota composition and function in middle-aged, healthy volunteers (72) and MCI 
patients respectively (73). Mechanisms may involve the production of short-chain fatty acids 
(SCFAs), branched-chain amino acids, and gut hormones. SCFAs, including acetate, 
butyrate, propionate, and lactate, can enter the circulatory system, and it is plausible that 
they may signal to the brain via this route (74). 
 
CONCLUSION 
Much evidence underlines the importance of diet in promoting health; it has been shown 
that nutritional protocols can direct the course and the outcomes of different pathologies 
affecting the central nervous system. The implementation of clinical trials will confirm the 
effectiveness of nutritional protocols developed not only for a specific disease but also for 
the demands of every single patient. Implementation of large-scale preventive interventions 
based on dietary patterns identified as being beneficial to brain health should be a research 
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• Dietary interventions are effective strategies against age-related cognitive decline 
and neurodegeneration 
 
• Individual nutritional components such as polyphenols, B-vitamins and long chain 
polyunsaturated fatty acids can have beneficial effects on cognitive performance 
 
• Different dietary patterns are suggested to exert a positive effect against cognitive 
decline in the elderly 
 
• Mechanisms may involve a reduction in neuroinflammation, an increase in 
endogenous antioxidant defence and a modulation of the gut microbiota structure 
and function. 
 
• Research should focus on large-scale preventive interventions ideally in conjunction 
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